IDF Europe's ongoing projects


Recognised aims to improve the identification of early cognitive impairment in people with type 2 diabetes, so that appropriate support could be promptly given. This project studies the biological mechanisms that cause structural and functional alterations in the retina in people with type 2 diabetes.


ISLET aims to improve the lives of people living with diabetes through a new advanced cell therapy. This project is working towards building and implementing a new and innovative programme for producing and marketing human pluripotent stem cell (hPSC)-derived advanced therapy medicinal products (ATMPs) for the treatment of people with T1D.

Trials at home

This project aims to improve patient health and drug development by making it easier for larger, more diverse and remote populations to participate in clinical trials. This project will provide practical recommendations to promote the widespread acceptance and implementation of Remote Decentralised Clinical Trials (RDCTs) across Europe.

We thank our strategic partners for their support of IDF Europe priority activities.

Boehringer Ingelheim

Special thanks to Lilly Diabetes and Novo Nordisk for their additional support of the IDF Europe Centenary of Insulin Campaign.

Lilly diabetes
Novo Nordisk